Plasma levels of angiogenic factors and circulating endothelial cells in essential thrombocythemia: correlation with cytoreductive therapy and JAK2–V617F mutational status

References

• Alonci A, Allegra A, Bellomo G, et al Evaluation of circulating endothelial cells, VEGF and VEGFR2 serum levels in patients with chronic myeloproliferative diseases. Hematol Oncol 2008;26:235–239.
   PubMed Web of Science ®Google Scholar
• Medinger M, Skoda R, Gratwohl A, et al Angiogenesis and vascular endothelial growth factor-/receptor expression in myeloproliferative neoplasms: correlation with clinical parameters and JAK2-V617F mutational status. Br J Haematol 2009;146:150–157.
   PubMed Web of Science ®Google Scholar
• Mesa RA, Hanson CA, Li CY, et al Diagnostic and prognostic value of bone marrow angiogenesis and megakaryocyte c-Mpl expression in essential thrombocythemia. Blood 2002;99:4131–4137.
   PubMed Web of Science ®Google Scholar
• Musolino C, Calabro’ L, Bellomo G, et al Soluble angiogenic factors: implications for chronic myeloproliferative disorders. Am J Hematol 2002;69:159–163.
   PubMed Web of Science ®Google Scholar
• Panteli K, Bai M, Hatzimichael E, et al Serum levels, and bone marrow immunohistochemical expression of, vascular endothelial growth factor in patients with chronic myeloproliferative diseases. Hematology 2007;12:481–487.
   PubMed Web of Science ®Google Scholar
• Wróbel T, Mazur G, Surowiak P, et al Increased expression of vascular endothelial growth factor (VEGF) in bone marrow of patients with myeloproliferative disorders (MPD). Pathol Oncol Res 2003;9:170–173.
   PubMed Web of Science ®Google Scholar
• Banks RE, Forbes MA, Kinsey SE, et al Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology. Br J Cancer 1998;77:956–964.
   PubMed Web of Science ®Google Scholar
• Weltermann A, Wolzt M, Petersmann K, et al Large amounts of vascular endothelial growth factor at the site of hemostatic plug formation in vivo. Arterioscler Thromb Vasc Biol 1999;19:1757–1760.
   PubMed Web of Science ®Google Scholar
• Elliott MA, Tefferi A. Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haematol 2005;128:275–290.
   PubMed Web of Science ®Google Scholar
• Monestiroli S, Mancuso P, Burlini A, et al Kinetics and viability of circulating endothelial cells as surrogate angiogenesis marker in an animal model of human lymphoma. Cancer Res 2001;61:4341–4344.
   PubMed Web of Science ®Google Scholar
• Mancuso P, Burlini A, Pruneri G, et al Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. Blood 2001;97:3658–3661.
   PubMed Web of Science ®Google Scholar
• Beerepoot LV, Mehra N, Vermaat JS, et al Increased levels of viable circulating endothelial cells are an indicator of progressive disease in cancer patients. Ann Oncol 2004;15:139–145.
   PubMed Web of Science ®Google Scholar
• Lin Y, Weisdorf DJ, Solovey A, et al Origins of circulating endothelial cells and endothelial outgrowth from blood. J Clin Invest 2000;105:71–77.
   PubMed Web of Science ®Google Scholar
• Zhang H, Vakil V, Braunstein M, et al Circulating endothelial progenitor cells in multiple myeloma: implications and significance. Blood 2005;105:3286–3294.
   PubMed Web of Science ®Google Scholar
• Wierzbowska A, Robak T, Krawczyńska A, et al Circulating endothelial cells in patients with acute myeloid leukemia. Eur J Haematol 2005;75:492–497.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2008;22:14–22.
   PubMed Web of Science ®Google Scholar
• Baxter EJ, Scott LM, Campbell PJ, et al Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005;365:1054–1061.
   PubMed Web of Science ®Google Scholar
• Gora-Tybor J, Jamroziak K, Szmigielska-Kaplon A, et al Evaluation of circulating endothelial cells as noninvasive marker of angiogenesis in patients with chronic lymphocytic leukemia. Leuk Lymphoma 2009;50:62–67.
   PubMed Web of Science ®Google Scholar
• Veikkola T, Karkkainen M, Claesson-Welsh L, et al Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res 2000;60:203–212.
   PubMed Web of Science ®Google Scholar
• Wolanskyj AP, Schwager SM, McClure RF, et al Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors. Mayo Clin Proc 2006;81:159–166.
   PubMed Web of Science ®Google Scholar
• Carobbio A, Finazzi G, Guerini V, et al Leukocytosis is a risk factor for thrombosis in essential thrombocythemia:interaction with treatment, standard risk factors, and Jak2 mutation status. Blood 2007;109:2310–2313.
   PubMed Web of Science ®Google Scholar
• Falanga A, Marchetti M, Vignoli A, et al Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera. Exp Hematol 2005;33:523–530.
   PubMed Web of Science ®Google Scholar
• Treliński J, Tybura M, Smolewski P, et al The influence of low-dose aspirin and hydroxyurea on platelet-leukocyte interactions in patients with essential thrombocythemia. Blood Coagul Fibrinolysis 2009;20:646–651.
   PubMed Web of Science ®Google Scholar
• Cortelazzo S, Finazzi G, Ruggeri M, et al Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med 1995;332:1132–1136.
   PubMed Web of Science ®Google Scholar
• Harrison CN, Campbell PJ, Buck G, et al Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 2005;353:33–45.
   PubMed Web of Science ®Google Scholar
• Nikolaidis I, Makrilia N, Xyla V, et al Bevacizumab may be active in myelofibrosis. Cancer Invest 2010;28:111–112.
   PubMed Web of Science ®Google Scholar
• Di Costanzo F, Mazzoni F, Micol Mela M, et al Bevacizumab in non-small cell lung cancer. Drugs 2008;68:737–746.
   PubMed Web of Science ®Google Scholar
• Sozer S, Wang X, Zhang W, et al Circulating angiogenic monocyte progenitor cells are reduced in JAK2V617F high allele burden myeloproliferative disorders. Blood Cells Mol Dis 2008;41:284–291.
   PubMed Web of Science ®Google Scholar
• Boveri E, Passamonti F, Rumi E, et al Bone marrow microvessel density in chronic myeloproliferative disorders: a study of 115 patients with clinicopathological and molecular correlations. Br J Haematol 2008;140:162–168.
   PubMed Web of Science ®Google Scholar
• Carmeliet P, Moons L, Luttun A, et al Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 2001;7:575–583.
   PubMed Web of Science ®Google Scholar
• Park JE, Chen HH, Winer J, et al Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. J Biol Chem 1994;269:25646–25654.
   PubMed Web of Science ®Google Scholar